Abstract
Introduction: Follicular lymphoma (FL) is the second most common form of B cell lymphoma and generally presents as an indolent and relatively slow-growing tumor. However, most FLs are incurable with a shortening of subsequent responses. Therefore, novel and more effective treatments are desperately needed. Tazemetostat is a first-in-class, selective, oral inhibitor of EZH2, a lysine methyltransferase that is mutated in about 25% of FL. Tazemetostat has been recently approved for relapsed/refractory FL after two or more lines of therapy in the presence of an EZH2 mutation or independent of an EZH2 mutation in the absence of other options. Areas covered: Here, the authors provide a review focusing on the molecular mechanisms of EZH2, clinical development of tazemetostat and other EZH2 inhibitors (EZH2i), as single-agent therapy and in combinatorial regimens. Finally, they provide a futuristic look at therapeutic approaches for this disease. Expert opinion: Tazemetostat monotherapy showed clinically meaningful and durable responses with a favorable toxicity profile, especially in EZH2 mutant lymphoma. Future studies should explore mechanism-based combinatorial regimens to maximize and prolong the anti-lymphoma effect.
Original language | English (US) |
---|---|
Pages (from-to) | 295-301 |
Number of pages | 7 |
Journal | Expert Opinion on Pharmacotherapy |
Volume | 23 |
Issue number | 3 |
DOIs | |
State | Published - 2022 |
Keywords
- EZH2
- epigenetics
- follicular lymphoma
- precision therapy
- tazemetostat
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)